



EUREOS

European Society of Eosinophilic
Oesophagitis

EUREOS ANNUAL REPORT

2024–2025

ADDRESS

EUREOS Scheuchzerstrasse 35
CH-8006 Zurich
Committee's Office

www.eureos.online
info.eureos@gmail.com
www.centerview.ch

EDITORIAL

DEAR COLLEAGUES,



As in every year for the past twelve, we gather to review EUREOS's progress. Our organization has grown steadily, becoming a reference in eosinophilic GI diseases and an essential partner in guidelines, education, and research on EoE. The growth of our membership, activities, and joint projects all reflect this trajectory.

Four years ago, I assumed the presidency with the enthusiasm to advance our young society, supported by a dedicated steering committee and a growing network of members and partners. Now is the time to assess both the past year's work and the outcomes of our strategy.

This period has been marked by three milestones that will shape EUREOS's identity: championing the first World EoE Day with patient organizations, launching the freely accessible, CME-accredited EUREOS Library, and building the world's largest collaborative EoE research network through EoE CONNECT. These achievements were possible thanks to the dedication of our members and the support of our partners, to whom I extend my sincere thanks.

Looking ahead, EUREOS will continue to serve its members, uphold scientific quality, and promote best practices for patients, while remaining a trusted partner for corporate members. I warmly wish our new President every success and look forward to supporting her as we continue to strengthen our society together.

Best regards,

A handwritten signature in blue ink, appearing to read 'Alfredo J. Lucendo'.

Alfredo J. Lucendo
President 2021–2025

ABOUT EUREOS




EUREOS is the meeting point for European physicians and researchers to share interdisciplinary knowledge on eosinophilic esophagitis and other eosinophilic gastrointestinal disorders. Our organisation continues to develop as a consolidated reference in communication, cutting-edge collaborative research and continuous training of professionals on eosinophilic esophagitis, eosinophilic gastroenteritis and eosinophilic colitis across Europe.

STEERING COMMITTEE

The EUREOS steering committee 2024–2025 consists of

- Alfredo Lucendo (President 2021–2025)
- Ulrike von Arnim (President-elect 2025–2027)
- Luc Biedermann (Treasurer)
- Arjan Bredenoord
- Matteo Ghisa
- Mirelle Kleuskens
- Helen Larsson
- Salvatore Oliva
- Christoph Schlag
- Francesca Racca

MEMBERS



EUREOS is currently supported by 318 members (+41 since the last general assembly) from different countries worldwide. Our members represent a broad spectrum of medical specialties, including adult and pediatric gastroenterology, allergology, immunology, pediatrics, primary care, pharmacy, nutrition, pathology, and otorhinolaryngology. We also include basic scientists from various disciplines who have a particular interest in EoE and other eosinophilic gastrointestinal diseases (EGIDs).

Members are welcome to participate in the annual general meeting, to propose activities for the advancement of our organisation, and to play an active role in decisions about the future activities of EUREOS.

Membership is free for physicians and scientists.

COMMUNICATION PLATFORM

The central communication element of EUREOS is its website, which covers the latest topics within EoE and places them in the context of everyday clinical practice. The website is primarily aimed at physicians, but also offers information for patients.



European Registry of Clinical, Environmental and Genetic Determinants in Eosinophilic Esophagitis

In 2016 EUREOS created an advanced multilingual EoE database with the aim to improve knowledge on epidemiology, its evolving trends, and on its burden to the health systems across Europe. The registry serves as a base for implementation of further prospective collaborative studies and is open to patients from all Europe. To date over 5000 patients of all ages have been recruited by 67 study sites in 4 European Countries. Detailed research objectives are the following:

- To describe the socio-demographical and clinical characteristics as well as personal antecedents of EoE patients.
- To examine the relationship between time of disease onset, length of diagnostic delay, and disease phenotypes.
- To determine the influence of environmental and genetic factors on the time of onset, natural history and course of EoE.
- To analyse the use, effectiveness, and safety of the different therapeutic interventions in EoE, both in short and long term, using the standardized set of outcomes.
- To examine the burden of disease costs associated with EoE in adults.

EoE CONNECT is run under the patronage of EUREOS with a scientific committee of ten international EoE experts. Contributors, that have added more than 30 patients in the EoE registry, can submit a study request to the scientific committee using the data in the EoE registry. Currently nine studies and several UEGW abstracts have been published using the EoE CONNECT database:

- Efficacy of proton pump inhibitor therapy for eosinophilic oesophagitis in 630 patients: results from the EoE connect registry *Pharmacol Ther.* 2020 Sep;52(5):798-807.
- Efficacy of Therapy for Eosinophilic Esophagitis in Real-World Practice. *Clin Gastroenterol Hepatol.* 2020 Dec;18(13):2903-2911.
- Proton pump inhibitor therapy reverses endoscopic features of fibrosis in eosinophilic esophagitis. *Dig Liver Dis.* 2021 Nov;53(11):1479-1485.
- EoE CONNECT, the European Registry of Clinical, Environmental, and Genetic Determinants in Eosinophilic Esophagitis: rationale, design, and study protocol of a largescale epidemiological study in Europe *Therap Adv Gastroenterol.* 2022 Feb 2;15:17562848221074204.
- Accurate and timely diagnosis of Eosinophilic Esophagitis improves over time in Europe.An analysis of the EoE CONNECT Registry. *United European Gastroenterol J.* 2022 Jun;10(5):507-517.
- Differences between childhood- and adulthood-onset eosinophilic esophagitis: An analysis from the EoE connect registry. *Dig Liver Dis.* 2023 Mar;55(3):350-359.
- Determinant factors for first-line treatment choice and effectiveness in pediatric eosinophilic esophagitis: an analysis of the EUREOS EoE CONNECT registry. *Eur J Pediatr.* 2024 Aug;183(8):3567-3578.
- Swallowed topical corticosteroids for eosinophilic esophagitis: Utilization and real-world efficacy from the EoE CONNECT registry. *United European Gastroenterol J.* 2024 Jun;12(5):585-595.
- Sex-Related Differences in the Presentation, Management and Response to Treatment of Eosinophilic Esophagitis: SEXEoE Study of EoE CONNECT. *United European Gastroenterol J* 2024;12(10):1388-1398.

EXPERT RECOMMENDATIONS

RENEWAL OF EUROPEAN GUIDELINES ON EOE

The current European Guidelines on diagnosis and management of EoE date back to 2017. The diagnostic and therapeutic armamentarium have developed since. A group of experts have been working in updating statements and providing best evidence to support clinical decisions in our patients. Last version of statements is currently being voting, and guidelines will be submitted for publication very soon. EUREOS EoE guidelines are developed with the endorsement of United European Gastroenterology.

EUREOS EXPERT RECOMMENDATIONS

Since its foundation, researchers and experts linked to EUREOS have collaborated to provide guidance on several essential aspects of clinical practice. Published between 2015 and 2023, the various consensus documents released have benefited from the collaboration of international organisations and colleagues from across the Atlantic from CEGIR and the AAAAI EGID Committee.

New projects are currently underway, focused on providing expert recommendations on complex issues for which there is no definitive evidence, which will be released soon.

The documents released by EUREOS in collaboration with other organisations have addressed essential aspects of EoE, and include the following:

- Monitoring Patients With Eosinophilic Esophagitis in Routine Clinical Practice - International Expert Recommendations. *Clin Gastroenterol Hepatol*. 2023 Sep;21(10):2526-2533.
- A Summary of the Meetings of the Development of a Core Outcome Set for Therapeutic Studies in Eosinophilic Esophagitis (COREOS) International Multidisciplinary Consensus *Gastroenterology*. 2021 Sep;161(3):778-784
- Therapeutic Studies in Eosinophilic Esophagitis (COREOS) International Multidisciplinary Consensus *Gastroenterology*. 2021 Sep;161(3):778-784.
- Development of a Core Outcome Set for Therapeutic Studies in Eosinophilic Esophagitis (COREOS): An International Multidisciplinary Consensus *Gastroenterology*. 2021 Sep;161(3):748-755.
- Development of a core outcome set for therapeutic studies in eosinophilic esophagitis (COREOS) *J Allergy Clin Immunol*. 2021 Jul 6;S0091-6749(21)01059-9.
- Proton pump inhibitor-responsive oesophageal eosinophilia: an entity challenging current diagnostic criteria for eosinophilic oesophagitis *Gut*. 2016 Mar;65(3):524-31.

EDUCATION

INTERNATIONAL EVENTS

As in previous years, the 7th annual scientific EUREOS EoE Symposium took place as hybrid event in parallel to UEGW 2024.

Main topics were:

- Topical therapies – proven concepts and new developments
(Thomas Greuter, Switzerland)
- EoE: Systemic or local disease? A debate among experts
(Mirelle Kleuskens, Netherlands, Adnan Custovic, UK)
- Challenging situations in the EoE Clinical Practice
(Javier Molina-Infante, Spain)

ONLINE EDUCATION PLATFORM



In 2022, EUREOS launched the EUREOS Library (<https://eureos.nubwebinar.com/>), an online education platform dedicated to EoE and other eosinophilic gastrointestinal disorders. It offers high-quality, up-to-date content from EUREOS members through courses, symposia, webinars, and podcasts covering all aspects of EoE, EGID, and related diseases. The courses are designed for a wide range of professionals, including gastroenterologists, pediatricians, allergists, ENT specialists, endoscopists, primary care physicians, nurses, dietitians, nutritionists, and researchers. EUREOS Library enables EACCME CME accreditation through five free activities with teaching and knowledge check.

Available courses:

- EUREOS Symposium 2024: Evidence and Uncertainty
- EUREOS Symposium 2023: Past, Present and Future
- EUREOS Symposium 2022: Clinical and Epidemiological Innovations in EoE
- EUREOS Online Course: Advancing Awareness and Knowledge for better Life with EoE
- EUREOS IV National Congress of Eosinophilic Esophagitis

PATIENT RELATIONS

World EoE Day 2025



The EoE Day Alliance, participated by EUREOS, was proud to launch World Eosinophilic Esophagitis Day (#EoEDay) a global awareness day dedicated to shining a light on Eosinophilic Esophagitis (EoE), a chronic and often underdiagnosed immune condition. Taking place on May 22, 2025, this important milestone brought together patient organizations from around the world including Spain, the USA, Australia, Italy, Austria, and Serbia, all working together to:

1. Raise awareness of EoE and its symptoms;
2. Encourage people to seek medical advice for signs like difficulty swallowing or persistent reflux; and
3. Advocate for better care, research and access to treatment, especially in underresourced countries.

As in 2024, EUREOS supported the World EoE Day on 22 May 2025 with several activities. To mark the European EoE Day, EUREOS has put together the second season of short one-minute informative sequences on EoE for those affected. Would you like to find out more? Please visit eureos.online.

ACKNOWLEDGEMENT

We thank our sponsors for their long standing financial support:

PLATINUM SPONSORS



GOLD SPONSORS



SPONSORS



